SAN.PA · PAR CAC 40 Euro Stoxx 50

Sanofi

Healthcare · Drug manufacturers

€85.71 −€0.24 (−0.28%) today

Closing price on Nov 11, 2026 · Source: Yahoo Finance

Consensus of 24 analysts

Buy

Median price target €99.00 +15.5%

Open: €85.70
Day range: 85.56 – €86.08
52-week range: 69.75 – €90.79
Volume: 366,014
Market cap: €102,686M
P/E (TTM): 24.8x
EPS (TTM): €3.45
EPS est. 2026: €8.88
P/E est. 2026: 9.7x
Dividend yield: n/a
Beta: 0.26
Payout: 119%

Analyst summary

Generated with AI · Nov 11, 2026, 14:46

Sanofi’s broad healthcare business spans immunology, rare diseases, oncology and vaccines, supported by research and development collaborations. Q3 2026 revenue rose +15.7% year on year to €15,233M, while net income increased more slowly and the net margin narrowed. The shares trade at 24.8x trailing earnings, against analyst forward P/E estimates of 9.7x for 2026 and 9.1x for 2027. Analysts are evenly split between Buy and Hold, with no Sell ratings.

1Q3 2026 revenue rose +15.7% year on year to €15,233M.
2The share price is €85.71, with a 24.8x trailing P/E.
3Analysts’ median target is €99.00, implying +15.5% upside.

Sanofi financials

Q3 2026 results, quarter ended Sep 30, 2026

Metric	Q3 2026	1-year change
Total revenue	€15,233M	+15.7%
Net income	€3,021M	+7.8%
Earnings per share	€2.52	+7.7%
Net margin	19.8%	−1.4 pp
Free cash flow	€5,167M	−0.1%
Debt / equity	0.27	−8.3%

Revenue and net income (€M)

Total revenueNet income

Quarter	Total revenue	Net income
Q3 2025	€13,170M	€2,802M
Q4 2025	€12,205M	−€801M
Q1 2026	€11,244M	€1,614M
Q2 2026	€12,300M	€343M
Q3 2026	€15,233M	€3,021M

Q3 2026 revenue increased +15.7% year on year to €15,233M, while net income rose +7.8% to €3,021M. The net margin fell 1.4 pp to 19.8%, indicating that profit growth lagged sales growth. Quarterly revenue moved from €13,170M in Q3 2025 to €12,205M in Q4, €11,244M in Q1 2026 and €12,300M in Q2, before the latest increase. Net income was volatile, including a loss of −€801M in Q4 2025 and a recovery to €3,021M in Q3 2026.

The results indicators report Q3 EPS of €2.52, up +7.7% year on year. Separately, the EPS consensus series records Q3 EPS of €3.550 against an estimate of €2.835, a +25.2% surprise; previous quarters in that series also beat estimates. Annual EPS estimates rise from €8.879 for 2026 to €9.426 for 2027, versus €6.400 in 2025. Q3 free cash flow was €5,167M, down −0.1%, and debt/equity was 0.27. The current P/E is 24.8x; estimated forward P/Es are 9.7x for 2026 and 9.1x for 2027.

Written by AI · Nov 11, 2026, 14:46

Sanofi earnings per share (EPS)

Consensus estimates

Period	EPS est.	1-year change
Current quarterQ4 2026 · Analysts: 9	€1.7251.37 – 2.11	+12.7%€1.530
Next quarterQ1 2027 · Analysts: 1	€2.0202.02 – 2.02	+7.5%€1.880
Current year2026 · Analysts: 20	€8.8798.48 – 9.27	+13.4%€7.830
Next year2027 · Analysts: 21	€9.4268.44 – 10.07	+6.2%€8.879

Forward P/E: 9.7x (2026) and 9.1x (2027) at the current price.

Actual and estimated EPS (€)

Actual EPSEstimated EPS

Quarter	Actual EPS	Estimated EPS
Q3 2025	€2.339	—
Q4 2025	€1.530	€1.466
Q1 2026	€1.880	€1.799
Q2 2026	€2.090	€1.900
Q3 2026	€3.550	€2.835
Q4 2026	—	€1.725
Q1 2027	—	€2.020

Year	Actual EPS	Estimated EPS
2022	€5.370	—
2023	€4.310	—
2024	€4.590	—
2025	€6.400	—
2026	—	€8.879
2027	—	€9.426

EPS trend

Quarter	EPS	YoY change
Q1 2027Estimated	€2.020	+7.4%
Q4 2026Estimated	€1.725	+12.7%
Q3 2026	€3.550est. €2.835 · surprise +25.2%	+51.8%
Q2 2026	€2.090est. €1.900 · surprise +10.0%	n/a
Q1 2026	€1.880est. €1.799 · surprise +4.5%	n/a
Q4 2025	€1.530est. €1.466 · surprise +4.4%	n/a
Q3 2025	€2.339	n/a

Year	EPS	Annual change
2027Estimated	€9.426	+6.2%
2026Estimated	€8.879	+38.7%
2025	€6.400	+39.4%
2024	€4.590	+6.5%
2023	€4.310	−19.7%
2022	€5.370	n/a

Normalised EPS according to the analyst consensus collected by Yahoo Finance; it may differ from the reported EPS in the results table.

Sanofi dividend

Yield and payments

Dividend yield (TTM)	n/a
Forward yield (next 12m)	4.8%
Dividend per share (TTM)	€0.00
Forward dividend (next 12m)	€4.12
Payout (TTM)	119%
Last dividend	€4.12May 5, 2026
Next ex-dividend date	n/a

Dividend per share by year (€)

PaidEstimated

Year	Dividend per share
2019	€3.07
2020	€3.15
2021	€3.20
2022	€3.33
2023	€3.56
2024	€3.76
2025	€3.92
est. 12m	€4.12

The trailing dividend yield is n/a and trailing dividend per share is listed as €0.00, although the latest recorded dividend was €4.12, with an ex-date of May 5, 2026. The estimated 12-month dividend is €4.12 per share, corresponding to a 4.8% forward yield. The stated payout is 119%, a level that merits attention when assessing the coverage of future distributions.

The dividend history shows a gradual increase, from €3.07 in 2019 to €3.92 in 2025, with €4.12 estimated for the next 12 months. No next ex-dividend date is available (n/d), so the timing of the next payment cannot be specified.

Written by AI · Nov 11, 2026, 14:46

Sanofi forecasts

24 analyst ratings

Buy50% Hold50% Sell0%

Consensus: Buy · 12 buy, 12 hold, 0 sell

1-year price forecast

Share price Price target (high, median, low)

12-month price targets
Target	Price	Upside
High	€110.00	+28.3%
Median	€99.00	+15.5%
Low	€78.00	−9.0%

Monthly close (last 12 months)
Date	Close
Nov 28, 2025	€85.76
Dec 31, 2025	€82.72
Jan 30, 2026	€79.20
Feb 27, 2026	€82.20
Mar 31, 2026	€82.72
Apr 30, 2026	€79.82
May 29, 2026	€75.29
Jun 30, 2026	€75.08
Jul 31, 2026	€74.47
Aug 31, 2026	€76.81
Sep 30, 2026	€72.64
Oct 30, 2026	€79.74
Nov 11, 2026	€85.71

Analyst opinion is positive but not unanimous: of 24 analysts, 12 (50%) rate the shares Buy and 12 (50%) Hold; none rate them Sell. The consensus is Buy. The median price target is €99.00, implying +15.5% upside from the current price.

Targets range from €78.00 (−9.0%) to €110.00 (+28.3%), showing a meaningful spread of views. EPS consensus points to €8.879 for 2026 and €9.426 for 2027, with estimated growth slowing from +38.7% to +6.2%. The target range and decelerating projected EPS growth temper the otherwise constructive consensus.

Written by AI · Nov 11, 2026, 14:46

Sanofi peers

Ticker	Company	Market cap (€M)	P/E	Price (€)	1-day change	52-week range
SAN.PA	Sanofi	102,686	24.8x	85.71	−0.28%	69.7590.79
BAYN.DE	Bayer	55,546	n/a	56.54	−0.95%	26.6457.78
REC.MI	Recordati	10,967	21.0x	52.70	−0.57%	43.7654.45
GRF.MC	Grifols	7,701	15.9x	11.32	−0.53%	8.4311.70
LLY	Lilly	1,275,805	46.5x	1,432.29 $	+1.44%	850.511,453.00
JNJ	Johnson & Johnson	675,925	42.6x	280.78 $	−0.47%	189.05283.25

Stocks quoted in another currency are shown in their trading currency.

At €102,686M, Sanofi’s market capitalisation is substantially above Bayer’s €55,546M and well ahead of Recordati at €10,967M and Grifols at €7,701M. Sanofi’s 24.8x trailing P/E is above Recordati’s 21.0x and Grifols’ 15.9x; Bayer’s P/E is n/a.

The US peers Lilly and Johnson & Johnson are larger by market capitalisation, at $1,275,805M and $675,925M respectively, and trade at 46.5x and 42.6x P/E. These comparisons span different markets and currencies, but show Sanofi’s valuation above the named European peers with available P/Es and below the two US peers.

Written by AI · Nov 11, 2026, 14:46

Risks, catalysts and conclusion

Generated with AI · Nov 11, 2026, 14:46

Risks

Clinical-development setbacks across Sanofi’s research programmes and collaborations could weaken future growth prospects.
A narrowing net margin despite faster revenue growth could persist and constrain profit conversion.
The 119% stated payout may put pressure on dividend coverage if earnings growth disappoints.

Catalysts

Successful progress in immunology, rare-disease and oncology research programmes could strengthen the future growth pipeline.
Effective execution of collaborations with biotechnology and AI partners could expand research opportunities.
Delivery of projected EPS growth of +38.7% in 2026 and +6.2% in 2027 could support investor confidence.

Conclusion

Sanofi combines a broad therapeutic and vaccine portfolio with strong Q3 revenue growth and a record of rising dividends. The latest quarter also shows slower profit growth than sales, a lower net margin and volatile quarterly earnings, while the stated payout is high. Analyst sentiment is positive overall, but split evenly between Buy and Hold. The valuation depends in part on delivering the projected EPS growth and sustaining dividend coverage.

Analysis written automatically by AI from Yahoo Finance market data on Nov 11, 2026, 14:46.

This content is for information only and is not financial advice or a recommendation to buy or sell securities. Ratings and price targets come from third-party analysts. Investing in the stock market involves the risk of losing capital.

Sanofi

Analyst summary

Sanofi financials

Q3 2026 results, quarter ended Sep 30, 2026

Revenue and net income (€M)

Sanofi earnings per share (EPS)

Consensus estimates

Actual and estimated EPS (€)

EPS trend

Sanofi dividend

Yield and payments

Dividend per share by year (€)

Sanofi forecasts

24 analyst ratings

1-year price forecast

Sanofi peers

Risks, catalysts and conclusion

Risks

Catalysts

Conclusion

What the AI agents think about Sanofi

More companies in Healthcare

More CAC 40 companies